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ABSTRACT Leukotrienes have been implicated in the
regulation of immune responses, including inflammation and
immediate hypersensitivity reactions. Here, we describe the
phenotypic analysis of leukotriene-deficient mice generated by
inactivation of the 5-lipoxygenase (SLO) gene. These
5LO(-/-) mice were unable to synthesize detectable levels of
leukotrienes and were more resistant to lethal anaphylaxis
induced by platelet-activating factor. The intensity of an acute
inflammatory response induced by arachidonic acid was sim-
ilar in 5LO(-/-) mice and controls. However, the response in
5LO(-/-) mice, but not in controls, could be virtually
eliminated by a cyclooxygenase inhibitor. These data suggest
that inflammatory responses are modulated by arachidonic
acid metabolites through a variety of interconnected mecha-
nisms. This has important implications for understanding the
early events of an inflammatory response and for designing
drugs for use in therapeutic intervention.
Leukotrienes belong to a family of biologically active mole-
cules called eicosanoids that are derived from arachidonic
acid (AA). The eicosanoids include both the cyclooxygenase
products (prostaglandins and thromboxanes), and the 5-li-
poxygenase (5LO) products, the leukotrienes. The conver-
sion of AA to leukotriene A4 (LTA4) by the enzyme 5LO is
the first step in the synthesis of all leukotrienes. LTA4 can
either be converted to leukotriene B4 (LTB4) by LTA4
hydrolase or be conjugated with reduced glutathione by LTC4
synthase to form leukotriene C4 (LTC4). LTC4 can undergo
further modification to yield leukotriene D4 (LTD4) and
leukotriene E4 (LTE4). LTC4 and its metabolites are often
referred to as the peptidyl leukotrienes, and these represent
what have in the past been referred to as the slow-reacting
substances of anaphylaxis (1).
The biologic activities of leukotrienes suggest that they are
mediators of acute inflammatory and immediate hypersensi-
tivity responses. Peptidyl leukotrienes, which are released by
leukocytes in response to inflammatory and immunologic
stimuli, cause contraction of endothelial cells, resulting in
increased permeability of postcapillary venules (2). The
peptidyl leukotrienes are also potent bronchoconstrictors (3)
and continue to be considered important mediators of allergic
diseases of the airways (4, 5). Both the peptidyl leukotrienes
and LTB4 increase the adhesion of leukocytes to endothelial
cells (2, 6). LTB4 is also a potent chemotactic factor for
neutrophils (7-9), and because it can also lessen the chemo-
tactic capacity of neutrophils over time, LTB4 has been
proposed to play a role in preventing migration of leukocytes
away from sites of inflammation (10).
The isolation of leukotrienes from inflammatory lesions
has led to speculation concerning their role in a number of
human diseases, including rheumatoid arthritis, asthma, in-
flammatory bowel disease, and psoriasis (5). In addition,
evidence has been presented suggesting that they play a role
in a broad spectrum of normal biological homeostatic re-
sponses, including those involved in reproductive physiology
(11), myelopoiesis (12), and calcium channel activation by
epidermal growth factors (13).
To date, our ability to address the role of leukotrienes in
various inflammatory diseases has depended on the use of
leukotriene receptor antagonists and 5LO inhibitors. To
circumvent this limitation, we have generated animals in
which the 5LO pathway has been inactivated by the targeted
disruption of the 5LO gene.
MATERIALS AND METHODS
Generation of 5LO(-/-) Mice. The targeting vector was
prepared from genomic clones containing the murine 5LO
gene identified by using a human 5LO cDNA (14) and is
identical to the corresponding region in the mouse genome,
except that a 1.3-kb fragment extending from the Aat II site
at the 3' end of intron 9 to the Sma I site in exon 10 has been
replaced by the neo gene in pJNS2 (15). This construct was
electroporated into the embryonic stem (ES) cell line
E14TG2a (16), and neomycin- and ganciclovir-resistant col-
onies were identified by following protocols previously de-
scribed (15). DNA was isolated from surviving colonies,
digested with EcoRI, and analyzed by Southern blotting using
probes located downstream of the targeting construct (Fig.
1A). Chimeric mice were generated with the 5LO-targeted
ES cell lines and were bred to either B6D2 or C57BL/6 mice.
Offspring were identified by Southern blot analysis of tail
DNA, using probes described above. Genotypes of the
5LO(-/-) mice were confirmed by screening with a 0.7-kb
Sma I fragment corresponding to sequences at the 3' end of
intron 9 and the 5' end of exon 10 (Fig. 1A).
Stimulated Release of Eicosanoids from Peritoneal Macro-
phages. Peritoneal macrophages were harvested from mice 3
days after intraperitoneal injection with 1 ml of 10% peptone.
Cells were cultured in 1.5 ml of Dulbecco's modified Eagle's
medium (DMEM) supplemented with 20 mM Hepes for 30
min. Supernatant was collected and replaced by medium
containing the Ca2+ ionophore A23187 at 5 ,ug/ml for an
additional 30 min. Supernatant was collected and the number
of cells in each well was verified by using a hexosaminidase
assay, carried out as described previously (17). The amounts
of LTC4, prostaglandin E2 (PGE2), and thromboxane B2
(TXB2) in the pre- and poststimulation supernatants were
determined by using enzyme immunoassay (EIA) kits (Cay-
men Chemicals, Ann Arbor, MI).
Abbreviations: 5LO, 5-lipoxygenase; AA, arachidonic acid; LTA4,
LTB4, etc., leukotriene A4, leukotriene B4, etc.; PAF, platelet-
activating factor; ES cell, embryonic stem cell; PGE2, prostaglandin
E2; TXB2, thromboxane B2; EIA, enzyme immunoassay; MPO,
myeloperoxidase.
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Induction of Inflammatory Responses in Mouse Ear Tissue.
The inside of the left ear of a mouse was painted with 20 ul
ofAA (100 mg/ml in acetone) while the right ear was treated
with 20 Al of acetone alone. Mice were sacrificed, and an
8-mm-diameter disc of tissue was punched from the center of
each ear. For analysis of edema formation, animals were
injected intravenously with either indomethacin (1 mg/ml in
0.1 M Na2CO3/0.15 M Na2HPO4, pH 7.4) and 0.5% Evans
blue dye (10 mg of indomethacin per kg of body weight) or
only 0.5% Evans blue dye solution [in phosphate-buffered
saline (PBS), 2.7 mM KCl/1.2 mM KH2PO4/138 mM NaCl/
8.1mM Na2HPG4, pH 7.5] prior to AA application. In several
myeloperoxidase (MPO) assays, mice received indomethacin
(10 mg/kg) prior to AA treatment.
Edema/Vascular Permeability Measurements. Edema was
measured by determining the wet weight of the ear punches.
To extract extravasated Evans blue dye, tissue samples were
incubated in 1 ml of formamide at 55°C for 1 hr. Evans blue
was quantified by measuring the absorbance of the forma-
mide extracts at 610 nm with a spectrophotometer (18).
MPO Assay. MPO was quantified according to a modified
method of Bradley et al. (19). Ear punches were homogenized
in 0.3 ml of PBS containing 0.5% hexadecyltrimethylammo-
nium bromide (HTAB). After homogenization and two
freeze/thaw cycles, homogenates were centrifuged at 10,000
x g for 20 min and MPO activity in the supernatant was
assayed by incubating 20 jul of diluted sample with 180 Al of
50 mM sodium phosphate buffer (pH 6.0) containing o-dia-
nisidine (0.2 mg/ml) and hydrogen peroxide (0.0006%). MPO
activity was quantified by comparison to dilutions of com-
mercially available MPO.
Platelet-Activating Factor (PAF)-Induced Anaphylaxis.
Mice received intravenous injections of 50 ug of PAF per kg
of body weight in bovine serum albumin (BSA) at 2.5 mg/ml
and propranolol at 0.05 mg/ml in saline. Survival was as-
sessed for 1 hr subsequent to injection of PAF.
RESULTS
Generation of 5LO(-/-) Mice. The targeting strategy that
we used to disrupt the 5LO gene is depicted in Fig. 1A.
Because no map was available for the murine 5LO gene, the
mouse genomic fragments used in the construction of the
5LO targeting plasmid, shown in Fig. 1A, were selected on
the basis of the map of the human SLO gene (20). The human
gene is composed of 14 exons, with the carboxyl-terminal
exons 8-14 encoding evolutionarily conserved domains, in-
cluding those that encode the active sites of the enzyme (20).
We therefore constructed a targeting plasmid that would
remove exonic sequences from this region of the gene. As
shown in Fig. 1A, homologous recombination ofour targeting
plasmid with the endogenous SLO gene results in replace-
ment of a 1250-bp Sma I-Aat II fragment with a PGK-Neo
cassette. This fragment, which encompasses the 3' end of
intron 9 and the 5' end of exon 10, includes the first 35 codons
of exon 10 of the human 5LO gene. As this region is highly
conserved, we expected that, even if the cell were able to
splice out the disrupted exon, the absence of these amino
acids would lead to an inactive enzyme.
The targeting plasmid was introduced into E14TG2a ES
cells by electroporation. Of the 487 G418- and ganciclovir-
resistant colonies that were isolated and expanded, 7 targeted
clones were identified by Southern blot analysis. These
clones contained a second hybridizing band in addition to the
14.4-kb band seen in the nontargeted cell line. Two of these
targeted ES cell lines, 100-130 and 100-90, are shown in Fig.
1B. In 6 of the 7 targeted lines, the additional band was the
size that would be expected to result from targeted integra-
tion of the plasmid into the SLO locus (Fig. 1B; 100-130). In
the seventh line, 100-90, the new band was slightly larger than
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FIG. 1. Targeting vector and homologous recombination at the
5LO locus. (A) Restriction maps of the targeting construct and of the
endogenous and disrupted loci. Exon 10 of the SLO gene is indicated
by the filled box, and the PGK-TK and PGK-Neo selection cassettes
are represented by empty boxes (PGK, phosphoglycerate kinase;
TK, thymidine kinase). Relevant restriction sites are abbreviated as
follows: A, Aat II; E, EcoRI; Ns, Nsi I; Sm, Sma I. The hatched
boxes indicate the probes used to detect homologous recombination
events by Southern blot analysis. (B) Southern blot analyses of
EcoRI-digested DNA from two targeted ES cell lines (ES), 100-130
and 100-90, and of tail DNA from 5LO(+/+), 5LO(+/-), and
5LO(-/-) mice derived from each. Blots were hybridized with the
1.5-kb Nsi I probe outside of the targeted region of the 5LO gene.
Sizes of DNA fragments are indicated in kb.
predicted, suggesting that a misalignment of DNA had oc-
curred prior to recombination (Fig. 1B; 100-90).
Mice homozygous for the mutated 5LO gene were derived
from four of the targeted lines. Homozygous and heterozy-
gous mice were identified by analysis of DNA from tail
biopsies. Interestingly, these analyses indicated that addi-
tional rearrangements occurred in mice derived from three of
the four targeted lines. To verify that the targeting event had
resulted in loss of genetic information necessary for the
expression of active SLO, DNA samples from SLO(-/-)
animals were examined by Southern blotting using as probe
a 700-bp Sma I fragment that recognizes the 3' end of intron
9 and the 5' end of exon 10. The genomic sequence recog-
nized by this probe is included in the segment ofthe SLO gene
replaced by the PGK-Neo gene during targeting. The 14.4-kb
EcoRI fragment in the endogenous locus (see above) was
detected by this probe in DNA from ES cells, SLO(+/+)
mice, and 5LO(+/-) mice but not in DNA from SLO(-/-)
mice (data not shown).
To verify that our targeting strategy abolished transcription
of wild-type 5LO mRNA, total cellular RNA was isolated
from stimulated peritoneal macrophages from SLO(-/-) and
SLO(+/+) mice and analyzed by reverse transcription poly-
merase chain reaction (RT-PCR). We detected the expected
fragment in macrophage RNA of 5LO(+/-) and SLO(+/+)
mice. However, this SLO transcript could not be detected in
RNA isolated from macrophages of5LO(-/-) mice (data not
shown). We conclude that not only have we deleted a critical
portion of the gene but also the targeted region of the SLO
gene was not transcribed into stable mRNA.
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Animals homozygous for the SLO mutation were also
present in the expected ratios, indicating that disruption of
the SLO locus had no effect on fetal development or survival
ofthe mice. 5LO(-/-) mice were indistinguishable in growth
and size from their 5LO(+/-) and 5LO(+/+) littermates.
Because the SLO gene is expressed primarily in cells of
myeloid lineage, and because leukotrienes have been reported
to affect the production ofcytokines known to affect lymphoid
activation and function, we screened for effects of the SLO
mutation on the development of myeloid and lymphoid pop-
ulations (data not shown). Peripheral white blood cell counts
were similar in 5LO(-/-) mice and 5LO(+/+) mice, and we
detected no differences in the ratios of polymorphonuclear
leukocytes (PMNs), monocytes, and lymphocytes in periph-
eral blood. The architecture of the major lymphoid organs
appeared normal by histologic examination. Two-color fluo-
rescence-activated cell sorter (FACS) analysis of thymocytes
with antibodies against CD4, CD8, and T-cell receptor a,8
showed no difference in the character of double-negative
(CD4-CD8-) or double-positive (CD4+CD8+) thymocyte pre-
cursors. Numbers of thymocytes expressing the T-cell recep-
tor a/3 and either CD4 orCD8 antigen were also identical in the
two groups of animals. Similarly, FACS analysis of cells
isolated from spleen and lymph nodes with antibodies to B220
and T-cell receptor a,3 revealed no differences in the ratios of
cells bearing these T- and B-cell markers.
Eicosanoid Production in 5LO(-/-) Mice. Calcium iono-
phore-stimulated macrophages have been shown to release
leukotrienes, prostaglandins, and thromboxanes (21). To
determine whether synthesis of these AA metabolites was
altered in our 5LO(-/-) mice, we measured the amounts of
LTC4, PGE2, and TXB2 released from macrophages derived
from 5LO(-/-) mice and control littermates. To accomplish
this, peritoneal macrophages were stimulated in vitro with the
Ca2+ ionophore A23187. Release of LTC4, PGE2, and TXB2
before and after stimulation was measured by EIA.
As can be seen in Fig. 2A, LTC4 production was not
detected from macrophages before stimulation with A23187.
After stimulation, however, LTC4 release from control mac-
rophages was increased by greater than 1000-fold, while no
release of LTC4 from 5LO(-/-) macrophages could be
detected. On the other hand, A23187 stimulation resulted in
enhanced release of PGE2 and TXB2 from both 5LO(-/-)
and control macrophages. Interestingly, the amounts of
PGE2 and TXB2 released from 5LO(-/-) macrophages after
stimulation were greater than the amounts released from the
cells of wild-type (+/+) mice (Fig. 2 B and C).
AA-Induced Edema. Leukotrienes are believed to be im-
portant mediators of inflammatory responses, including in-
creased vascular permeability resulting in edema formation.
To assess the contribution ofproducts ofthe SLO pathway to
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FIG. 3. Dye extravasation in 5LO(+/+) and 5LO(-/-) mice. (A)
5LO(+/+) mouse (right) and 5LO(-/-) mouse (left) received 0.5%
Evans blue just prior to the application ofAA in acetone to the left
ear and acetone alone to the right ear. (B) 5LO(+/+) (right) and
5LO(-/-) (left) mice were treated in an identical manner as mice in
A, except that indomethacin was added to the Evans blue such that
each animal received 10 mg of indomethacin per kg of body weight.
Photographs of the mice were taken 1 hr after AA treatment.
tissue was induced by topical application ofAA. Edema was
measured by determining the wet weight of the ear tissue at
30 min to 3 hr after AA treatment, when the response was
maximal (22). In addition, alterations in vascular permeabil-
ity were determined by injecting animals with Evans bluejust
prior to the application ofAA and quantifying the amount of
Evans blue in the ear biopsy. Evans blue binds to serum
proteins and thus can be used to visualize and quantify
alterations in vascular permeability (18). As can be seen by
observation ofthe mice shown in Fig. 3A, little difference was
observed between control and 5LO(-/-) animals. In both
5LO(-/-) and control mice, alterations in vascular perme-
ability followed by extravasation of serum proteins caused
AA-treated ears to become darker blue than untreated ears.
Biopsy samples were obtained from AA-treated and un-
treated ears. Although mean ear weight and extravasation of
Evans blue tended to be lower in 5LO(-/-) animals com-
pared with control littermates, these differences did not reach
statistical significance (Fig. 4 A and B, P = 0.14 and 0.096,
respectively).
As discussed above, our initial experiments with peritoneal
macrophages showed enhanced production of cyclooxygen-
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FIG. 2. Ca2+ ionophore-induced eicosanoid production in 5LO(+/+) and 5LO(-/-) mice. Peritoneal macrophages (1 x 106) from two
5LO(+/+) and two 5LO(-/-) mice were cultured in 1.5 ml of tissue culture medium for 30 min. Supernatant was collected and replaced by
medium containing the Ca2+ ionophore A23187 at 5 ,g/ml. Cells were incubated for an additional 30 min with the ionophore, and the supernatant
was collected. The amounts ofLTC4 (A), PGE2 (B), and TXB2 (C) in the pre- (amounts too low to be shown) and post- (hatched bars) stimulation
supernatants were assessed by EIA. After ionophore stimulation and supernatant collection, the number of adherent macrophages was verified
by using a hexosaminidase assay.
Proc. Natl. Acad. Sci. USA 91 (1994)























w/o Indo with Indo
FIG. 4. Edema and dye extravasation in 5LO(+/+) (o) and
5LO(-/-) (o) mice. Prior to the application of2 mg ofAA in acetone
to the left ear and acetone alone to the right ear, mice received either
0.5% Evans blue or 0.5% Evans blue plus indomethacin (Indo; 10 mg
of kg body weight). After 1 hr, animals were sacrificed, 8-mm-
diameter discs were taken from each ear, and the difference in weight
between the right ear and left ear for each animal was recorded (A).
The extravasation of dye into the tissue was then quantitated by
extraction ofdye with formamide and measurement of absorbance at
a wavelength of 610 nm. For each animal the A610 obtained for the
right ear was subtracted from that obtained for the left ear (B). Error
bars indicate SEM.
controls. To examine the contribution of this increased
production on the inflammatory response in 5LO(-/-) an-
imals, we carried out a second series of experiments in which
animals were treated with indomethacin, a potent inhibitor of
cyclooxygenases, prior to application of AA. As can be seen
in Fig. 4A, edema in indomethacin-treated animals, as deter-
mined by increased ear weight, was significantly lower in
5LO(-/-) mice than in 5LO(+/+) controls (P = 0.0011). In
addition, indomethacin treatment significantly lowered the
AA-stimulated extravasation of Evans blue in 5LO(-/-)
mice, not only relative to control animals (Fig. 4B, P =
0.0016) but also in comparison with 5LO(-/-) mice that had
not been pretreated with indomethacin (Fig. 4B, P = 0.045).
In contrast, indomethacin treatment had no effect on AA-
stimulated extravasation of Evans blue in 5LO(+/+) control
mice (Fig. 4B, P = 0.286). These results were consistent with
changes detected by direct observation of the AA-treated
mice. As can be seen in Fig. 3B, the treated ear of the
5LO(-/-) mice remained pink with only a faint halo of blue
at the outer edge. This is in contrast to the treated ear in
5LO(+/+) mice, which turned uniformly deep blue.
AA-Induced Neutrophil Infiltration. One of the early cel-
lular events in acute inflammation is the margination of
leukocytes, primarily neutrophils. This response can be
measured by using the neutrophil specific enzyme MPO as an
indicator of neutrophil accumulation. To examine the effect
of 5LO deficiency on neutrophil accumulation associated
with a localized inflammatory response, AA was applied to
the inner ear of 5LO(-/-) and control mice, ear biopsy
samples were obtained after 7 and 24 hr, and theMPO content
of each sample was determined. In all cases, the MPO
activity in untreated control ears was below the level of
detection for this assay. Seven hours after AA application,
MPO was easily detected in tissue obtained from the
5LO(+/+) animals, indicating that neutrophils had been
recruited to the site of inflammation. Although the average
MPO content of ears from 5LO(-/-) mice was lower than
that of 5LO(+/+) mice, the difference was not significant
(Fig. 5, P = 0.07). After 24 hr, MPO content in treated ears
from both 5LO(+/+) and 5LO(-/-) mice had decreased.
However, as the decrease was greater for 5LO(-/-) mice,
a significant difference was seen in MPO content between
these mice and control littermates (Fig. 5, P = 0.001). Using
reasoning similar to that described above for examination of
edema in 5LO(-/-) mice, we measured the effect of indo-
methacin on MPO content in the 5LO(+/+) and 5LO(-/-)
mice 7 hr after AA application. As seen in Fig. 5, although
7hr 7hr 24hr
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FIG. 5. Neutrophil infiltration in 5LO(+/+) (o) and 5LO(-/-)
(o) mice. For each mouse, the left ear was treated with AA and the
right ear was treated with vehicle alone. A second group of mice
received indomethacin prior to AA treatment. Mice were sacrificed
at 7 or 24 hr, and neutrophil infiltration was assessed by measuring
differences in MPO activity between AA-treated and control ears.
Error bars indicate SEM.
indomethacin treatment did not alter neutrophil migration in
control animals, the same treatment significantly inhibited
migration in the 5LO-deficient animals relative to controls (P
= 0.003).
PAF-Induced Anaphylaxis. PAF, a lipid autocoid, is a
potent inducer of anaphylaxis in mice (23, 24). Intravenous
injection of as little as 10 ug/kg can cause pulmonary
hypertension, altered vascular permeability, and broncho-
spasm resulting in death. While the exact mechanism by
which PAF causes these effects is not understood, it has been
suggested that many of these physiologic changes can be
attributed largely to PAF-induced release of leukotrienes
(24-26). To test this hypothesis, 17 leukotriene-deficient
animals and 16 control littermates were injected with PAF at
50 p,g/kg and monitored for the occurrence of lethal shock.
Administration of PAF at this concentration resulted in the
death of all of the 5LO(+/+) controls, while 8 of the
5LO(-/-) animals survived. Analysis of these results using
a x2 test revealed that SLO(-/-) animals are significantly
more resistant than controls to lethal shock induced by PAF
administration (P = 0.0016). However, as not all of the
5LO-deficient animals survived, and those that did showed
various degrees of shock, other factors must also contribute
to the anaphylactic response.
DISCUSSION
In this paper we describe a system which offers a more direct
means of investigating the role of leukotrienes in a broad
array of biological processes. By using gene targeting to
inactivate the SLO gene in the mouse genome, we created
mice incapable of synthesizing leukotrienes. This indicates
that, unlike the cyclooxygenase pathway, only one enzyme is
capable of initiating the first step of the biosynthetic pathway
leading to leukotrienes. The phenotype of these 5LO(-/-)
mice has proved interesting and informative, not only be-
cause it has allowed us to begin to define with certainty the
role that leukotrienes play in particular immune responses
but also because it has revealed that a number of physiologic
processes occur in an apparently normal manner in the
absence of leukotrienes. For example, we observed no ob-
vious abnormalities in leukocyte cell populations in
5LO(-/-) mice. While it is possible that a more detailed
examination in the future may reveal subtle differences, the
most reasonable interpretation of these results is that leuko-
trienes, while perhaps capable of influencing certain aspects
of hemopoiesis, are not essential for production and devel-
opment of cells in the myeloid and lymphoid lineages.
The previously described chemotactic and algesic activi-
ties of LTB4 (7-9, 27), along with the observation that LTC4
and LTD4 cause increased vascular permeability (2), led us to
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believe that 5LO(-/-) mice would differ from control mice
in their response to stimuli, such as AA, that have been
shown to cause acute inflammation (22, 28). Surprisingly, we
found that leukotriene deficiency did not greatly alter the
response of mice to AA-induced inflammation. This suggests
that an alternate leukotriene-independent pathway can me-
diate inflammatory responses to AA in 5LO(-/-) animals.
This pathway appears to be dependent on the products of the
cyclooxygenase pathways, as it can be blocked by treatment
of the animals with indomethacin prior to AA application.
This is consistent with the finding that ionophore-stimulated
macrophages from 5LO(-/-) mice produced increased lev-
els of PGE2 and TXB2. Macrophages from 5LO(-/-) mice
may be compensating for the inability to synthesize leuko-
trienes by upregulating the biosynthesis of prostaglandins
and thromboxanes. It is also possible that, because AA
serves as the substrate for the biosynthetic pathways leading
to the production of both prostanoids and leukotrienes, the
inactivation of the SLO pathway may result in overproduc-
tion of prostanoids by increasing the amount of substrate
available for cyclooxygenase. While the cyclooxygenase-
dependent pathway in 5LO(-/-) mice yielded only slightly
less neutrophil migration in response to AA after 7 hr, after
24 hr significantly less MPO activity was detected in
5LO(-/-) mice than in controls. This suggests that, while
the products of the cyclooxygenase pathway are able to
induce the early accumulation of neutrophils, either directly
or through secondary mechanisms, they are less effective at
maintaining this inflammatory response. Thus, the products
of the cyclooxygenase pathway cannot compensate for the
role of leukotrienes in maintaining neutrophils at the site of
inflammation. These results are consistent with the previous
proposal that leukotrienes play a role in preventing the
migration of neutrophils from sites of inflammation (10).
Preliminary phenotypic analysis of the 5LO-deficient mice
indicates that leukotrienes are not necessary for normal
development or reproduction. As expected, however, leu-
kotrienes do play a role in acute inflammatory responses,
although, in the absence of leukotrienes, alternative mecha-
nisms can evoke the characteristic signs of inflammation.
This suggests that the effectiveness of leukotriene inhibitors
may be masked unless cyclooxygenase inhibitors are co-
administered and that inhibition of binding of leukotrienes to
specific receptors may prove more effective than inhibition of
SLO activity, as receptor antagonists may not cause the same
increased release of products of the cyclooxygenase path-
way.
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